UFP Technologies Delivers Seventh Straight Earnings Beat in Q3 2026

UFP Technologies reported adjusted earnings per share of $2.88 for its third quarter of 2026, beating the consensus estimate. Revenue of $172.4 million also topped expectations and grew from the same period a year earlier, mostly on organic growth.

Gross margin widened to 29.4% from 27.7% a year ago. That expansion meant sales growth translated into an even larger earnings gain, with net income rising year over year. Adjusted EBITDA and adjusted operating income both grew faster than revenue.

MedTech remained the primary engine, with segment sales climbing 12.5% on what CEO Mitch Rock characterized as broad-based demand across the portfolio. A common concern with contract manufacturers of this size is customer concentration, and management addressed it directly: the top five MedTech customers collectively grew 11.7% year to date, suggesting the growth is not dependent on a single program or account.

Rock acknowledged that scheduled program transfers to the company's Dominican Republic facility and related margin improvements are running behind plan. SG&A also grew faster than sales, rising to 13.4% of revenue from 12.3% a year ago, a gap worth monitoring if it persists.

Looking toward 2027, management signaled it is investing in additional capacity at DAS Medical to support double-digit growth and is actively pursuing acquisitions. The company is also working to expand its credit facility, which Rock described as increasing UFP's capacity to onboard larger businesses. No quantitative guidance was provided for the year ahead.